(R1400-ST-1113) Phase I Study of REGN1400 in Combination with Erlotinib or Cetuximab Administered in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) or Head and Neck Cancer (SCCHN)

The primary objective of the study is to characterize the safety profile of REGN1400 administered intravenously (IV) as monotherapy and in combination with erlotinib or cetuximab in patients with advanced NSCLC, CRC or SCCHN.

Study Number: 

I 219912

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.